Australia's Nexsen rises on early rollout of GBS screening test

Nexsen

26/03/2026 24:59

** Nexsen NXN.AX rises as much as 9.1% to A$0.180

** Stock on track for third consecutive session of gains

** Nano biotech firm executes global rollout strategy for StrepSure

** Co to enable early market entry across U.S., India, Hong Kong, other select regions while progressing towards U.S. regulatory approval

** Co targets U.S. FDA submission in Q4 2026

** StrepSure is a test to detect Group B Streptococcus (GBS) bacteria - which causes pneumonia, meningitis and others - in pregnant women

** YTD, NXN gains 12.5%

 (Reporting by Aamir Sheik Khalid in Bengaluru)

 ((Aamir.SheikKhalid@thomsonreuters.com))